Ipsos has launched a Global Ophthalmology Therapy Monitor - the latest addition to its Syndicated Real World Evidence Portfolio - in the big five EU markets plus Switzerland, Japan and Canada.
Other markets are available on demand.
Like all the others in the series, the Ophthalmology monitor will combine actual patient data with perceptions of treating doctors, promising a 360-degree view of the evolving treatment landscape and with specific coverage of use of anti-VEGF therapy amongst patients with age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Subscribers can track how often each patient is treated, based on doctors' decisions about injection frequency; and will receive updates on new therapy and device launches, including physicians' awareness of them, their likelihood of adoption post launch and suitable patient types.
Sarah Brown (pictured), Director of Real World Evidence in Global Diseases at Ipsos, says of the launch: 'The treatment of retinal diseases is an increasingly competitive area, with treatment practices continuously evolving in an effort to optimise treatments and reduce the burden on patients. Our new study will enable clients to track the new therapies and, interestingly, the new devices coming to market that may further improve the burden of dosing frequency and, in turn, patient compliance'.
Web site: www.ipsos.com .
All articles 2006-18 written and edited by Mel Crowther and/or Nick Thomas.